The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.
 
James Lloyd Wade
Employment - Johnson & Johnson (I)
Stock and Other Ownership Interests - Celgene; Seagen
 
Corey J. Langer
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Abbott Biotherapeutics; ARIAD; Bayer/Onyx; Bristol-Myers Squibb; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Lilly/ImClone; Merck
Research Funding - Advantagene (Inst); Ariad (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst); Stem CentRx (Inst)
 
Mary Redman
No Relationships to Disclose
 
Charu Aggarwal
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; Lilly
Speakers' Bureau - Genentech (I); Novartis (I); Pfizer (I)
Research Funding - Genentech/Roche (Inst); Incyte (Inst); Macrogenics (Inst); Millennium (Inst); Nektar (Inst)
 
Jeffrey D Bradley
No Relationships to Disclose
 
Jeffrey Crawford
Consulting or Advisory Role - Merck; Novartis; Pfizer
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer; Clovis Oncology; Genentech/Roche (Inst); GTx (Inst); Morphotek (Inst)
Travel, Accommodations, Expenses - Kirin Pharmaceuticals; Roche
Other Relationship - Celgene; G1 Therapeutics; Janssen; Merrimack; Roche
 
Jieling Miao
No Relationships to Disclose
 
Katie Griffin
No Relationships to Disclose
 
Roy S. Herbst
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Lilly; Merck; Pfizer
Research Funding - Genentech; Merck
 
Karen Kelly
Honoraria - Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - ARIAD; ARIAD; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; G1 Therapeutics; Genentech/Roche; Lilly; Lilly; Synta
Research Funding - Abbvie (Inst); Celgene (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Millennium (Inst); Novartis (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Roche
 
David R. Gandara
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Celgene; Clovis Oncology; Genentech; Guardant Health; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; Response Genetics; Sanofi; Synta
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech (Inst); Johnson & Johnson (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - ARIAD; AstraZeneca; Biothera; Clovis Oncology; Genentech; Genentech; Gensignia Life Sciences; Janssen; Lilly; Merck
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)